Avecris, officially AVECRIS Pte. Ltd, is a biotechnology company based in Singapore.[1] It is developing a non-viral gene delivery platform for use in gene therapy and genetic vaccination.[2]
Organization
| Name | Position | Notes |
|---|---|---|
| Dennis Mak | CEO | - |
| Sushmita Poddar | Director of R&D | - |
| Rachel Loh | Research Scientist | - |
| Volker Patzel | Chief Scientific Officer | - |
Investors
Alameda Research invested in AVECRIS.[3]
AVECRIS also participated in the 2022 cohort of First Flight Venture Center (FFVC)'s WheelsUP Accelerator, co-funded by the Biomedical Advanced Research and Development Authority (BARDA).[4]
In July 2022, AVECRIS was selected as a winner of the Golden Ticket Competition by the Bakar BioEnginuity Hub and the Cystic Fibrosis Foundation.[5]
External links
AVECRIS PTE. LTD. (201735118Z). Companies.sg. Retrieved March 26, 2023, from http://archive.today/2023.03.26-162037/https://www.companies.sg/business/201735118Z/AVECRIS-PTE-LTD ↩︎
Home. AVECRIS. Retrieved December 7, 2021, from https://web.archive.org/web/20211207084703/http://avecris.com/ ↩︎
Shubber, K., & Elder, B. (2022, December 6). Revealed: the Alameda venture capital portfolio. Financial Times. http://archive.today/2022.12.12-024608/https://www.ft.com/content/aaa4a42c-efcc-4c60-9dc6-ba6cccb599e6 ↩︎
WheelsUP Accelerator. First Flight Venture Center. Retrieved March 26, 2023, from http://archive.today/2023.03.26-162652/https://www.ffvcnc.org/wheelsup ↩︎
CF Foundation and Bakar Labs Announce Winners of First-Ever Golden Ticket Competition. (2022, July 21). Cystic Fibrosis Foundation. http://archive.today/2023.03.26-163323/https://www.cff.org/news/2022-07/first-ever-golden-ticket-winners ↩︎
